DeepMed Research

Natera

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2004-01-01

Employees: 3K

Market Cap: -

Website: http://www.natera.com

Introduction: Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Clinical Trials

BESPOKE Study of ctDNA Guided Immunotherapy

Completed

Conditions: Non-small Cell Lung Cancer
Colorectal Cancer
Melanoma

First Posted Date: 2021-02-21

Last Posted Date: 2024-08-15

Lead Sponsor: Natera, Inc.

Target Recruit Count: 290

Registration Number: NCT04761783

Locations: 🇺🇸
Natera, San Carlos, California, United States

BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer

Active, not recruiting

Conditions: Colorectal Cancer
Colon Cancer

First Posted Date: 2020-02-11

Last Posted Date: 2023-12-12

Lead Sponsor: Natera, Inc.

Target Recruit Count: 1788

Registration Number: NCT04264702

Locations: 🇺🇸
San Carlos, San Carlos, California, United States

The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)

Active, not recruiting

Conditions: Kidney Transplant Rejection

Interventions: Diagnostic Test: Prospera

First Posted Date: 2019-09-17

Last Posted Date: 2024-08-06

Lead Sponsor: Natera, Inc.

Target Recruit Count: 5000

Registration Number: NCT04091984

Locations: 🇺🇸
UT Southwestern, Dallas, Texas, United States
🇺🇸
Einstein Medical Center, Philadelphia, Pennsylvania, United States
🇺🇸
The Cleveland Clinic Foundation, Cleveland, Ohio, United States

and more 50 locations

Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection

Completed

Conditions: Transplant Rejection
Allograft Rejection
Complications

First Posted Date: 2019-06-13

Last Posted Date: 2025-03-18

Lead Sponsor: Natera, Inc.

Target Recruit Count: 110

Registration Number: NCT03984747

Locations: 🇺🇸
Natera Inc., San CArlos, California, United States
🇺🇸
Balboa United California Institute of Renal Research, San Diego, California, United States
🇺🇸
Children's Hospital at Montefiore, Bronx, New York, United States

and more 1 locations

Natera Ovarian Cancer Detection Assay

Terminated

Conditions: Adnexal Mass

First Posted Date: 2018-04-02

Last Posted Date: 2020-02-06

Lead Sponsor: Natera, Inc.

Target Recruit Count: 12

Registration Number: NCT03485651

Locations: 🇺🇸
Magee-Women's Hospital of UPMC, Pittsburgh, Pennsylvania, United States

SNP-based Microdeletion and Aneuploidy RegisTry (SMART)

Completed

Conditions: 22q11 Deletion Syndrome
Angelman Syndrome
DiGeorge Syndrome
Trisomy 18
Cri-du-Chat Syndrome
Trisomy 21
Trisomy 13
Monosomy X
Sex Chromosome Abnormalities
Prader-Willi Syndrome

First Posted Date: 2015-03-06

Last Posted Date: 2021-01-29

Lead Sponsor: Natera, Inc.

Target Recruit Count: 20960

Registration Number: NCT02381457

Locations: 🇦🇺
Royal Prince Alfred, Camperdown, New South Wales, Australia
🇸🇪
Sahlgrenska University Hospital, Gothenburg, Sweden
🇺🇸
University of California, San Francisco, San Francisco, California, United States

and more 18 locations

Multiple Gestation Study

Completed

Conditions: Trisomy 18
Sex Chromosome Abnormalities
Trisomy 13
Trisomy 21

First Posted Date: 2014-10-30

Last Posted Date: 2019-08-26

Lead Sponsor: Natera, Inc.

Target Recruit Count: 354

Registration Number: NCT02278536

Locations: 🇲🇾
Fetal Medicine & Gynaecology Centre, Petaling Jaya, Selangor, Malaysia
🇺🇸
Carnegie Hill Imaging for Women, New York, New York, United States
🇺🇸
Office of Dr. Robert Carpenter, Houston, Texas, United States

and more 5 locations

High Risk Multiple Gestation Study

Completed

Conditions: Trisomy 21
Sex Chromosome Abnormalities
Trisomy 13
Trisomy 18

First Posted Date: 2014-10-30

Last Posted Date: 2019-06-13

Lead Sponsor: Natera, Inc.

Target Recruit Count: 99

Registration Number: NCT02278874

Locations: 🇺🇸
Long Island Jewish Medical Center, Glen Cove, New York, United States
🇺🇸
Mt. Sinai Hospital, New York, New York, United States
🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States

and more 1 locations

Development of Non-invasive Prenatal Test for Microdeletion and Other Genetic Syndromes Based on Cell Free DNA

Completed

Conditions: Sex Chromosome Abnormalities
Microdeletion Syndromes
Trisomy 21
Trisomy 18
Trisomy 13

First Posted Date: 2014-04-10

Last Posted Date: 2019-08-26

Lead Sponsor: Natera, Inc.

Target Recruit Count: 216

Registration Number: NCT02109770

Locations: 🇺🇸
Natera, San Carlos, California, United States
🇺🇸
Children's Hospital Of Philadelphia, Philadelphia, Pennsylvania, United States

Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood

Completed

Conditions: Trisomy 21
Sex Chromosome Abnormalities
Trisomy 18
Trisomy 13
Microdeletion Syndromes

First Posted Date: 2013-05-14

Last Posted Date: 2020-12-30

Lead Sponsor: Natera, Inc.

Target Recruit Count: 1059

Registration Number: NCT01852708

Locations: 🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Saint Peter's University Hospital, New Brunswick, New Jersey, United States
🇺🇸
Natera, Inc., San Carlos, California, United States

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy